Group 2 innate lymphoid cells (ILC2s) regulate tissue inflammation and repair after activation by cell-extrinsic factors such as host-derived cytokines. However, the cell-intrinsic metabolic pathways that control ILC2 function are undefined. Here we demonstrate that expression of the enzyme arginase-1 (Arg1) during acute or chronic lung inflammation is a conserved trait of mouse and human ILC2s. Deletion of mouse ILC-intrinsic Arg1 abrogated type 2 lung inflammation by restraining ILC2 proliferation and dampening cytokine production. Mechanistically, inhibition of Arg1 enzymatic activity disrupted multiple components of ILC2 metabolic programming by altering arginine catabolism, impairing polyamine biosynthesis and reducing aerobic glycolysis. These data identify Arg1 as a key regulator of ILC2 bioenergetics that controls proliferative capacity and proinflammatory functions promoting type 2 inflammation.
The innate lymphoid cell (ILC) family orchestrates immunity, inflammation, metabolic homeostasis and tissue repair in multiple tissues, including intestine, liver, adipose, skin and lung 1, 2 . Group 2 ILCs (ILC2s) are the dominant ILC population in human and murine lung, where they act as key initiators of allergen-and nonallergen-induced type 2 inflammation 1,3-5 and promote airway tissue repair 6 . ILC2s are activated by cell-extrinsic environmental cues such as the cytokines interleukin-25 (IL-25), IL-33 and thymic stromal lymphopioetin 1, 2 . However, the cell-intrinsic pathways that regulate ILC2 effector function remain poorly characterized. In particular, regulation of cell metabolism is a critical determinant of adaptive lymphocyte development and function 7, 8 , although whether cell-intrinsic metabolic signals influence ILC biology is unknown. The enzyme arginase-1 (Arg1) has been identified as a marker of fetal intestinal ILC precursors and adult lung ILC2s 9, 10 , although the functional significance of Arg1 enzymatic activity in ILCs remains unclear.
Arg1 metabolizes the amino acid l-arginine to generate urea and ornithine, which is further metabolized into the downstream metabolites proline and polyamines that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively [11] [12] [13] . Although homeostatic l-arginine metabolism occurs primarily in the liver to complete the urea cycle, immune cells can serve as critical extrahepatic sites of Arg1 activity during infection and tissue inflammation [12] [13] [14] [15] [16] . Particularly in the context of cancer or type 2 cytokine-driven inflammation in the intestine, liver and skin, Arg1 activity is a key signature of alternatively activated macrophages 15, 16 (AAMacs). AAMac-derived Arg1 acts primarily extrinsically, promoting wound healing and tissue fibrosis by triggering collagen synthesis by fibroblasts or by limiting T cell responses via nutrient deprivation of l-arginine 14, [17] [18] [19] . In contrast, evidence supporting the functional significance of AAMac-derived Arg1 enzymatic activity in the lung remains controversial. For example, models targeting macrophage-specific Arg1 have failed to recapitulate the effects observed in studies using global inhibition of Arg1 to dampen airway inflammation [19] [20] [21] [22] [23] , which suggests that other cell populations might be responsible for Arg1's ability to promote the development of lung disease. We demonstrate here that Arg1 has a critical cellintrinsic role in regulating ILC2 metabolism and the development of type 2 inflammation.
RESULTS

Constitutive Arg1 expression in precursor and mature ILC2s
Arg1 expression has been reported in a population of ILC precursors in the fetal intestine and in mature ILC2s in the lung 9, 10 . Whether Arg1 is differentially expressed in distinct adult ILC precursors and mature ILC populations, as well as how this might be influenced by the tissue microenvironment, remains poorly characterized. Examination of bone marrow hematopoietic stem cells (HSCs), common lymphoid progenitors (CLPs) and the common innate lymphoid progenitor (CHILP) in reporter mice that express yellow fluorescent protein under control of the Arg1 promoter (Arg1 YFP ) did not show any expression of Arg1-YFP (Fig. 1a) , which suggests that upregulation of Arg1 in adult bone marrow occurs at a later developmental checkpoint during subset differentiation of the ILC lineages. Consistent with this, analysis of Arg1-YFP expression in lineage-specified bone marrow ILC2 precursors that lack KLRG1 (termed ILC2Ps) 24 showed high expression of Arg1-YFP equivalent to that observed in mature KLRG1 + ILC2s (Fig. 1b) . Taken together, these data identify Arg1 as a marker of lineage-committed ILC2 precursors in adult bone marrow.
To investigate whether Arg1 expression in mature ILC2s is influenced by the cells' distinct tissue microenvironment, we examined Arg1 expression in ILC2s isolated from various lymphoid, mucosal and adipose tissues. ILC2s in the lung expressed high amounts of Arg1, as measured both by intracellular staining and by expression of Arg1-YFP (Fig. 1c) . Further flow cytometric profiling of mature KLRG1 + ILC2s isolated from multiple tissues of Arg1 YFP mice, including spleen, mesenteric lymph node, small intestine, large intestine and epididymal white adipose tissue (Fig. 1d) , indicated that constitutive Arg1 expression represents a conserved trait of mature ILC2s across lymphoid and nonlymphoid tissues.
Mouse ILC2s express Arg1 in inflamed lung tissue
In contrast to lymphoid tissues and barrier surfaces such as the intestine that contain all three subsets of ILCs, the murine lung is dominated by ILC2s 3, 6 . Given the role of Arg1 in regulating lung homeostasis in the context of infection and inflammation 15, 16, 25, 26 , we sought to examine which cell populations are the dominant sources of Arg1. Unbiased flow cytometric analysis of total numbers of Arg1-YFP-expressing cells in lungs of naive Arg1 YFP mice showed that the majority of Arg1 was expressed by lineage-negative (Lin − ) cells that expressed CD90, CD25, CD127 and IL-33R, identifying them as ILC2s (Fig. 1e,f) . Comprehensive examination of several innate and adaptive immune cell lineages from the lungs of Arg1 YFP mice confirmed that ILC2s were the dominant cellular source of Arg1 under homeostatic conditions (Fig. 1g) .
ILC2s can promote type 2 inflammation in the lung in response to a variety of allergic and nonallergic stimuli 1,2 , although the cell-intrinsic factors regulating ILC2s' proinflammatory functions remain poorly characterized. To investigate whether ILC2-intrinsic Arg1 influences lung inflammation, we used a mouse model of acute allergeninduced airway inflammation. Intranasal administration of papain to Arg1 YFP mice resulted in elevated Arg1 mRNA expression in the lung compared to that in PBS-treated controls (Fig. 2a) , correlating with increased frequencies of ILC2s in the lung parenchyma (Fig. 2b) . The ILC2s continued to express high amounts of Arg1-YFP after allergen exposure (Fig. 2c) , resulting in elevated frequencies and total numbers of Arg1-expressing ILC2s compared to those in PBS-treated control mice (Fig. 2d,e) . Further, unbiased analysis of total Arg1-YFP + cells showed that ILC2s constituted a major source of Arg1 expression in the inflamed lung (Fig. 2f,g ). These data suggest that ILC-intrinsic expression of Arg1 influences the development and/or progression of lung inflammation.
Human ILC2s express Arg1 during lung disease Elevated expression of Arg1 and dysregulation of arginine metabolism have been reported in people diagnosed with asthma [25] [26] [27] [28] , chronic obstructive pulmonary disease 29, 30 (COPD) or idiopathic pulmonary fibrosis 17 (IPF). However, the cellular sources of the enzyme in human lung disease are incompletely understood and presumed to be limited to the myeloid lineage 11, 12, 31 . Using primary lung tissue obtained from individuals diagnosed with COPD or IPF, we next sought to determine whether Arg1 is expressed by ILCs during inflammatory lung disease in humans. Flow cytometric analysis of Lin − CD127 + ILCs identified all group 1 ILC (ILC1), ILC2 and group 3 ILC (ILC3) populations in human explant tissues (Fig. 3a) , although the total ILC frequency and subset distribution did not seem to differ significantly between disease states ( Supplementary Fig. 1a,b) . However, examination of intracellular Arg1 expression showed a pattern of differential expression among ILC subsets in which Arg1 expression by IL-33R + ILC2s was comparable to that by CD14 + CD16 + myeloid cells (Fig. 3b,c) . Arg1 expression in ILC2s did not differ significantly between people diagnosed with COPD and those diagnosed with IPF ( Supplementary  Fig. 1c ), which suggests that Arg1 expression might be a more generalized signature of these innate cells during inflammatory conditions and could represent a novel target for clinical therapies modulating arginine metabolism.
Deletion of ILC-intrinsic Arg1 dampens airway inflammation
To investigate the role of ILC2-derived Arg1, we generated a genetic mouse model that deletes Arg1 from ILCs using a Cre recombinase targeting cells expressing the IL-7Rα chain (Il7r Cre/+ ). Fate-mapping analysis using Il7r Cre/+ mice crossed to Rosa26 floxSTOP-eYFP mice showed that all lung ILC2s were marked with a history of IL-7Rα expression (Fig. 4a) . Notably, although CD4 + T cells, B cells and NK cells were also marked by a history of IL-7Rα expression ( Supplementary Fig. 2) , none of those cells expressed Arg1-YFP under steady-state conditions or during papain-induced lung Fig. 3 ). Therefore, use of the IL-7Rα Cre recombinase in combination with Arg1 flox/flox mice generates a mouse that lacks Arg1 specifically in ILCs (referred to as Arg1 ∆ILC here). Transcriptional ( Fig. 4b ) and flow cytometric ( Fig. 4c) analysis confirmed efficient deletion of Arg1 expression in lung ILC2s.
To test whether ILC-intrinsic Arg1 has a role in the development of lung inflammation, we treated Arg1 flox/flox , Arg1 +/+ Il7r Cre/+ control and Arg1 ∆ILC mice with PBS or papain and assessed them for immunologic and pathologic parameters of type 2 lung inflammation. All groups treated with PBS had equivalent frequencies of lung ILC2s (Fig. 4d,e) , which suggests that despite constitutive expression of Arg1, the enzyme was not required for the development, maturation or maintenance of ILC2s. Although exposure to papain resulted in increased frequencies (Fig. 4d,e ) and total numbers (Fig. 4f) of ILC2s in the lungs of Arg1 flox/flox and Arg1 +/+ Il7r Cre/+ mice compared with PBS-treated controls, loss of ILC-intrinsic Arg1 expression severely diminished papain-induced ILC2 responses in Arg1 ∆ILC mice ( Fig.  4d-f) . The lack of an ILC2 response correlated with decreased Arg1 expression in lung homogenates from Arg1 ∆ILC mice compared to Arg1 flox/flox and Arg1 +/+ Il7r Cre/+ mice ( Fig. 4g) , consistent with ILC2s being a critical regulator of Arg1 in the inflamed lung.
ILC2s are the primary source of the type 2 cytokines IL-5 and IL-13 during acute papain-induced inflammation, and these cytokines are critical for driving eosinophilia and the type 2 helper T (T H 2) cell subset of CD4 + T cell responses, respectively 4, 5 . Correlating with the reduction in ILC2 numbers, expression of Il5 (Fig. 4h) and Il13 ( Fig. 4i ) in lung homogenates was significantly decreased in papain-treated Arg1 ∆ILC mice compared to Arg1 flox/flox and Arg1 +/+ Il7r Cre/+ controls. Further, we observed decreased frequencies of IL-5 + IL-13 + ILC2s in Arg1 ∆ILC mice compared to those in Arg1 flox/flox mice ( Fig. 4j,k) , demonstrating that Arg1 expression is critical for optimal ILC2 cytokine effector function.
Although papain administration resulted in elevated numbers of CD45 + immune cells (primarily eosinophils) in the bronchoalveolar lavage fluid compared to those in control mice (Fig. 4l) , this was significantly reduced in the absence of ILC-intrinsic Arg1 (Fig. 4l,m) . Additionally, histological examination of the lungs showed that although exposure to papain resulted in clusters (Fig. 4n) . Collectively, these results define an essential role for ILC-intrinsic Arg1 expression in promoting acute type 2 inflammation in the lung.
Arg1 regulates ILC2 responses in chronic lung inflammation
In addition to their role in regulating the development of acute lung inflammation, ILC2s have been implicated in the progression or resolution of chronic lung inflammation, including in IPF 32 and helminth-parasite-induced lung remodeling 33, 34 . We next sought to test the involvement of ILC-derived Arg1 during chronic lung inflammation. Infection with the helminth parasite Nippostrongylus brasiliensis leads to the development of chronic lung inflammation characterized by increased amounts of type 2 cytokines and heightened Arg1 expression 35, 36 . Although Arg1 flox/flox mice exhibited a twofold increase in the frequency of ILC2s in the inflamed lung 1 month after infection, compared to naive controls, loss of ILC-intrinsic Arg1 prevented the generation of ILC2 responses ( Supplementary  Fig. 4a,b ) and was associated with decreased Arg1 expression in the inflamed lung (Supplementary Fig. 4c) . Similarly, in a mouse model of elastase enzyme instillation that leads to chronic damage to the alveolar septa partially mimicking the emphysematous pathology observed in COPD 37, 38 , we found that absence of ILC-intrinsic Arg1 prevented the generation of robust ILC2 responses ( Supplementary  Fig. 4d,e) , was associated with decreased Arg1 expression in lungs (Supplementary Fig. 4f ) and reduced the severity of emphysematous lung pathology (Supplementary Fig. 4g ). Taken together, these data highlight a conserved role for ILC-intrinsic Arg1 in controlling ILC2 responses in both acute and chronic models of lung inflammation.
ILC3 function is independent of ILC-intrinsic Arg1
Expression Fig. 5a ,b) and ILC3/ILC2 ratios ( Supplementary Fig. 5c,d Fig. 5e ).
Collectively, these data demonstrate that Arg1 activity controls optimal ILC2, but not ILC3, responses.
Lung inflammation is independent of myeloid Arg1
In addition to its association with ILCs, Arg1 expression is an effector signature of AAMacs, although the functional significance of myeloid-derived Arg1 activity during type 2 inflammation in the lung remains controversial [19] [20] [21] [22] [23] . Fate-mapping analysis of Il7r Cre/+ Rosa26 floxSTOP-eYFP mice showed that a minor population of macrophages showed a history of IL-7Rα expression (Fig. 5a) , and only a f small proportion of macrophages expressed Arg1-YFP during acute papain-induced inflammation (Fig. 5b) . Flow cytometric analysis did not show any significant difference in macrophage frequencies (Fig. 5c) , and we observed equivalent expression of macrophageintrinsic Arg1 mRNA ( Fig. 5d) and protein ( Fig. 5e) in the inflamed lungs of Arg1 flox/flox and Arg1 ∆ILC mice after papain exposure, indicating that AAMac accumulation and Arg1 expression are not impaired in Arg1 ∆ILC mice.
To test whether myeloid sources of Arg1 can act extrinsically to influence the magnitude of ILC2 responses and/or the development of papain-induced airway inflammation, we deleted Arg1 expression in macrophages and neutrophils using Cre recombinase under control of the Lyz2 (LysM) promoter 19, 40 (Arg1 ∆Lyz2 ). Absence of Arg1 in LysM + myeloid cells did not prevent the generation of robust lung ILC2 responses to papain (Fig. 5f,g ), nor did it influence the development of airway eosinophilia (Fig. 5h) or lung inflammation (Fig. 5i) . Taken together, these results indicate a selective requirement for ILC-intrinsic Arg1 in the development of acute airway inflammation, revealing an unexpected degree of cellular specificity with respect to the role of this enzyme in the lung.
Arg1 controls optimal ILC2 proliferation
The lack of a robust ILC2 response in the absence of cell-intrinsic Arg1 metabolic function could be due to impaired cell survival and/or reduced proliferative capacity. We found that deletion of Arg1 had no significant effect on the frequencies of 7AAD + annexin V + apoptotic ILC2s in the lungs of either PBS-treated or papain-treated mice (Supplementary Fig. 6a-c) , which suggests that the absence of ILCintrinsic Arg1 does not influence ILC2 survival under homeostatic conditions or during acute lung inflammation. To test whether loss of Arg1 affects ILC2 proliferation, we examined intracellular expression of the proliferation marker Ki67 in ILC2s isolated ex vivo during acute papain-induced lung inflammation. A high proportion of lung ILC2s from Arg1 flox/flox and Arg1 +/+ Il7r Cre/+ mice were Ki67 + cells (38-44%) (Fig. 6a,b) , indicating that those mice mounted a strong effector response to the papain allergen. In contrast, deletion of ILC-intrinsic Arg1 severely restrained ILC2 proliferation, resulting in significantly decreased frequencies (Fig. 6a,b) and cell numbers (Fig. 6c) of Ki67 + ILC2s compared to Arg1 flox/flox and Arg1 +/+ Il7r Cre/+ mice. To test directly whether cell-intrinsic Arg1 enzymatic activity is required for regulation of ILC2 proliferation, we sortpurified activated ILC2s from wild-type mice treated with recombinant murine IL-33 (rmIL-33) and tracked cellular division in the presence or absence of the selective Arg1 inhibitor N ω -hydroxy-nor-arginine (nor-NOHA) (Fig. 6d) . Within 48 h, nearly 80% of the ILC2s treated with dimethylsulfoxide (DMSO; controls) had undergone at least one division, and more than 20% had undergone three to five divisions (Fig. 6e,f) . Compared to controls, cells subjected to Arg1 enzymatic inhibition showed greatly decreased division, with more than 45% of the cells remaining undivided (Fig. 6e,f) . Consistent with our in vivo papain studies, the lack of division by the nor-NOHA-treated cells was not associated with increased cell death ( Supplementary  Fig. 6d) . Collectively, these studies demonstrate an essential role for Arg1 enzymatic activity in controlling the maximal proliferative capacity, but not survival, of activated ILC2s.
Arg1 inhibition disrupts amino acid metabolism
Arginine can be catabolized through several enzymatic pathways to yield a diverse set of metabolic intermediates that serve as substrates for downstream cellular and bioenergetic processes ( Supplementary  Fig. 7a and refs. 11,31,41,42 ). We hypothesized that the lack of proliferation in Arg1-deficient ILC2s might be associated with an imbalance among these metabolic substrates due to the disruption of Arg1 activity and possible compensation by the other enzymatic pathways to catabolize the excess arginine. To examine this, we first cultured IL-33-activated ILC2s in the presence or absence of nor-NOHA and measured the relative abundance of metabolites using liquid chromatography coupled with mass spectrometry (Supplementary Fig. 7b ). As expected, inhibition of Arg1 resulted in increased amounts of arginine in nor-NOHA-treated cells (Fig. 7a) , confirming that ILC2s express functional Arg1. Whereas DMSOtreated cells showed high abundance of the immediate downstream products ornithine and proline, the amounts of these metabolites were comparatively severely diminished in cells subjected to Arg1 inhibition (Fig. 7b,c) . We did not observe any corresponding increase in metabolites associated with two other main arginine catabolic pathways that would generate either citrulline-argininosuccinate via nitric oxide synthase (Fig. 7d) or creatine-creatinine biosynthesis via l-arginine:glycine amidinotransferase (Fig. 7e) , which suggested that excess arginine is probably not diverted through these pathways to compensate for the absence of Arg1. 
npg
A r t i c l e s
Changes in the size of a metabolite pool can result from either altered production or an altered consumption rate within the cell 41, 43 . Therefore, to further examine the metabolic fate of arginine in activated ILC2s, we traced the incorporation of uniformly enriched U-13 C-l-arginine isotope in ILC2s in the presence or absence of Arg1 activity. Whereas we observed rapid and almost complete entry of 13 C-l-arginine into ornithine (Fig. 7f,g ) and proline (Fig. 7h,i) in DMSO-treated ILC2s, with saturation kinetics being quickly achieved, this process was severely diminished in cells treated with Arg1 inhibitor, indicating that arginine is the primary precursor for both molecules in activated ILC2s. Further, inhibition of Arg1 activity also resulted in severely diminished entry of 13 C-l-arginine into biosynthesis of the ornithine-derived polyamine metabolite spermidine (Fig. 7j,k) . Notably, reversible interconversion between proline and ornithine metabolite pools is a well-appreciated reaction in mammalian cells 42 , supporting the conclusion that ornithine-derived polyamines, rather than ornithine and proline themselves, are a primary fate of l-arginine catabolism in ILC2s.
Taken together, these data indicate a model in which disruption of Arg1 in ILC2s is not associated with enhanced metabolism of nitric oxide synthase or l-arginine:glycine amidinotransferase (Supplementary Fig. 7a ) but does prevent the generation of l-arginine-derived polyamines (Supplementary Fig. 7a) , molecules that are known to regulate cell growth and survival 31, 41 .
Arg1 regulates maximal ILC2 glycolytic capacity
Proteins are just one component of a diverse set of nutrient substrates that immune cells can use to fuel their growth 7, 44 , raising the question of whether Arg1 metabolism influences bioenergetic pathways in addition to amino acid catabolism. In particular, the induction of aerobic glycolysis is a hallmark of effector lymphocyte metabolism 7 , although whether this reprogramming is used by ILCs during activation has never been examined. First, to characterize the bioenergetic profile of ILC2s during activation, we sort-purified lung IL-33R + ILC2s and T H 2 cells from mice treated with rmIL-33 ( Fig. 8a) and measured the cellular oxygen-consumption rate (OCR) and extracellular acidification rate (ECAR), indicators of mitochondrial respiration and aerobic glycolysis, respectively. ILC2s showed both elevated spare respiratory capacity (Fig. 8b,c) and high ECAR (Fig. 8d,e) in comparison to T H 2 cells, suggesting that ILC2s possess the capacity to augment mitochondrial respiration above basal conditions compared to T H 2 cells and strongly engage aerobic glycolysis. To test specifically whether Arg1 enzymatic activity can influence the respiratory or glycolytic capacity of ILC2s, we activated lung ILC2s with rmIL-33 in vivo and treated the cells ex vivo with nor-NOHA to inhibit Arg1 activity during measurement of ECAR and OCR. ILC2 spare respiratory capacity was not substantially affected by Arg1 inhibition (Fig. 8f,g ), which suggests that this enzyme does not have a notable effect on oxidative phosphorylation in ILC2s. In contrast, inhibition of Arg1 resulted in severely diminished maximal glycolytic capacity (Fig. 8h,i) , which indicates a critical regulatory role for Arg1 in influencing glucose metabolism in activated ILC2s.
Together with the trace analysis of arginine metabolites, these data provide evidence for a previously unrecognized aspect of this biochemical pathway in which Arg1 enzymatic activity acts on multiple biosynthetic and bioenergetic pathways to function as a metabolic checkpoint that controls ILC2 proliferation and effector function driving type 2 inflammation. npg DISCUSSION ILC2s can promote pathologic inflammation or host-protective tissue repair in the lung after activation by cell-extrinsic environmental cues such as alarmins and cytokines 1, 2 . However, the cell-intrinsic metabolic pathways that regulate ILC2 effector function are undefined.
Here we demonstrate a selective and essential role for cell-intrinsic Arg1 expression in regulating the proliferation and effector function of ILC2s required to promote acute and chronic type 2 airway inflammation. Inhibition of Arg1 enzymatic activity disrupted multiple components of ILC2 metabolic programming by altering arginine catabolism and limiting aerobic glycolysis, which indicates that Arg1 enzymatic activity serves as an essential checkpoint controlling ILC2 metabolism and the development of type 2 inflammation. We found that unlike Arg1 in macrophages, which requires induction by type 2 cytokines 15, 16 , Arg1 was constitutively expressed in bone marrow ILC2 progenitors and maintained in mature cells across diverse tissue environments. This leads to the question of when Arg1 is turned on during ILC development. Although HSCs, CLPs and CHILP did not express Arg1, examination of an ILC2 lineagecommitted bone marrow precursor lacking KLRG1 (ILC2P) 24 showed Arg1 expression equivalent to that in mature ILC2s. This upregulation of Arg1 expression in ILC2Ps occurs before the cells express transcripts for the effector cytokines IL-5 and IL-13 (ref. 24) , which might provide a rationale for why a previous study using IL-5-promoter-driven Cre to delete Arg1 showed no significant effects on ILC2 responses 9 . Of note, the constitutive Arg1 expression in ILC2s is independent of IL-4-or IL-13-STAT6 signaling 9 , leaving the molecular and cytokine cues that induce Arg1 expression in need of further investigation.
Until the identification of ILC2s as a constitutive source of Arg1, expression of this enzyme was thought to be a defining trait of the myeloid lineage, particularly of AAMacs, in which it serves to regulate wound healing, fibrosis and suppression of T cell responses 11, [14] [15] [16] . Our study suggests an unexpected degree of cellular specificity in the role of this enzyme, as deletion of myeloid cell sources of Arg1 via Lyz2-promoter-driven expression of Cre recombinase did not affect ILC2 responses or dampen papain-induced airway inflammation. Although further analysis using additional models of myeloid cell depletion is required to determine the reasons for this cellular compartmentalization of Arg1 function, it may provide a rationale for reconciling paradoxical reports of the role of Arg1 during type 2 lung inflammation. Previous studies using deletion of myeloid-cellintrinsic Arg1 failed to recapitulate the effects observed when global chemical inhibition or absence of hematopoietic-cell-restricted Arg1 dampens airway inflammation [19] [20] [21] [22] [23] . The data presented here demonstrate that deletion of ILC-intrinsic Arg1 acts to limit the magnitude of the ILC2 response itself, thereby diminishing the cells' proinflammatory capacity and preventing the development of acute and chronic type 2 inflammation in the lung. Notably, myeloid-cell-intrinsic Arg1 expression must be induced via AAMac polarization, a process that is partially dependent on ILC2-derived type 2 cytokines 45, 46 , thus revealing an additional, indirect mechanism by which ILC2s control Arg1 metabolism during inflammatory conditions. Elevated ILC2 responses have been reported in a number of human inflammatory disorders of the intestine, skin and lung barrier sites 1 . Particularly in the lung, dysregulation of L-arginine metabolism and Arg1 expression has been observed in people diagnosed with inflammatory diseases such as asthma [25] [26] [27] [28] , COPD 29, 30 and IPF 17 . Further, dietary supplementation with l-arginine and chemical inhibition of Arg activity are being evaluated as clinical therapies for the treatment of asthma 25, 26, 28 . Despite these clinical correlations, the mechanisms by which this enzyme regulates lung inflammation are incompletely understood and are assumed to be largely due to a reciprocal effect of increased nitric oxide and smooth muscle contractility in the absence of Arg1 (refs. 26,30) . Further, the identities of the sources of human Arg1 are controversial and incompletely defined. Using primary lung tissue from people with COPD and IPF, we observed selective expression of Arg1 by IL-33R + ILC2 populations but not by other ILC subsets. Although the significance of this restricted expression pattern is not yet clear, IL-33R expression is strongly enhanced on human ILC2s in response to cytokine signals 47 and therefore may represent a more activated state that ILC2s gain in inflamed tissue. Taken together with 
npg
A r t i c l e s the mouse mechanistic data, our studies suggest that Arg1 metabolic control of ILC2 function is a critical determinant of both acute and chronic type 2 inflammation in the lung and thus may represent a previously unrecognized axis for improvement of targeted therapeutics. Despite constitutive expression of Arg1 in bone marrow ILC2 progenitors, the absence of Arg1 did not seem to affect ILC2 development or maturation. Instead, Arg1 activity profoundly influenced the cells' ability to proliferate and exert their proinflammatory function after activation. This suggests a clear demarcation in the role of this enzyme in regulating the inflammatory, but not the homeostatic, state of ILC2s, perhaps because of the differential metabolic requirements of proliferating cells compared to those at rest. Inhibition of Arg1 and the subsequent decreased catabolism of arginine into ornithine resulted in an imbalance of amino acid metabolites, especially reduced synthesis of polyamines from l-arginine. Polyamine metabolites have been linked to diverse biological processes such as proliferation, apoptosis and cellular stress responses 31, 41 , and further biochemical studies will be required to investigate the fates of these molecules in ILC2 biology.
Amino acids are one of a large array of nutrients used for cell growth 7, 44 , provoking the question of whether Arg1 influences other aspects of ILC2 metabolic programming. We found that the effect of Arg1 was not limited to arginine catabolism-it also resulted in severe inhibition of the ability of these cells to engage in maximal rates of aerobic glycolysis (also known as Warburg metabolism 7, 8 ) to fuel proliferation. Although the effects of Arg1 on arginine and glucose metabolism might not be directly linked and probably involve a complex imbalance of many metabolic intermediates, it is remarkable that disruption of a single urea-cycle enzyme profoundly influences such distinct metabolic pathways, and this may lead to a new understanding of the importance of this enzyme beyond the classical urea cycle. As both a constitutive and an inflammatory source of arginase, ILC2s seem to occupy a unique functional niche mimicking both Arg1-dependent homeostatic hepatocyte function and inflammationinduced myeloid cell function. Critically, however, mammalian survival depends on hepatocyte-intrinsic Arg1 expression above any hematopoietic source of the enzyme 12, 31 , perhaps reflecting an evolutionary compartmentalization of arginase activity that fulfills the primary biological need of mammals for urea production while also limiting the proinflammatory consequences of Arg1-driven ILC2 activation. Understanding how Arg1 metabolism is integrated into the broader metabolic networks that govern the ability of ILCs and other innate immune cells to meet the biosynthetic and bioenergetic demands created during tissue inflammation may reveal new therapeutic targets for the treatment of numerous human inflammatory and metabolic diseases.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Mice. C57BL/6J (wild-type) mice were purchased from the Jackson Laboratory. Arg1 flox/flox , Lyz2-Cre, RORc(γt) gfp/gfp , Foxp3 eGFP , Rag1 −/− and Rosa26 floxSTOP-eYFP mice on a C57BL/6J background were purchased from the Jackson Laboratory and bred in-house. Rag2 −/− Il2rg −/− mice were from Taconic Farms (Hudson, NY). Arg1 YFP mice on a C57BL/6 background 9,10 were generously provided by Richard Locksley (University of California, San Francisco). Il7r Cre/+ mice on a C57BL/6 background 48 were provided by H.-R.R. and were used only as heterozygotes. For all Cre-flox studies, littermate controls were used and animals were cohoused after weaning. Male and female mice were used at 7-20 weeks of age. In individual experiments, all animals were age-and sex-matched; exact numbers of animals used per experiment are indicated in figure legends. All mice were maintained in specific-pathogenfree facilities at the University of Pennsylvania or Weill Cornell Medicine. All protocols were approved by both the University of Pennsylvania and the Weill Cornell Medicine Institutional Animal Care and Use Committees. 
Isolation of cells from mouse tissue.
For isolation of cells from lymphoid tissues, tissues were pressed through 70-µm cell strainers using the plunger of a 3-ml syringe and washed with DMEM wash media (Dulbecco's modified Eagle's medium with 10% FBS (Denville Scientific), 1% l-glutamine (Gibco), 1% penicillin-streptomycin (Gibco)), and any remaining red blood cells were lysed. We isolated cells from bone marrow by flushing out the marrow from cleaned bones using a syringe containing DMEM wash media. Red blood cells were lysed with ACK buffer (Lonza). Isolation of cells from bronchoalveolar lavage fluid and lung tissue was done as described 6 . We flushed the lungs with two washes of 1 ml of cold PBS via a thin tube inserted into a cut made in the trachea. Lungs were then perfused with 10 ml of PBS through the right ventricle of the heart before removal. Lung lobes were cut into small pieces with scissors and digested with 2 mg/ml collagenase D (Roche) in PBS for 45 min at 37 °C with vortexing every 10 min. Samples were pressed through 70-µm cell strainers and washed with DMEM wash media, and any remaining red blood cells were lysed with ACK buffer. Isolation of lymphocytes from epididymal white adipose tissue was done as described 49 . Briefly, tissue was minced with scissors and then digested with 1 mg/ml collagenase type II (Sigma-Aldrich) at 37 °C with shaking at 200 r.p.m. for 60-90 min. Digested tissues were passed through 70-µm cell strainers and washed with DMEM. The adipocyte layer was removed after centrifugation, and red blood cells were lysed with ACK buffer. Isolation of cells from the lamina propria of the large and small intestine was done as described 50 . Single-cell suspensions from all tissues were used for subsequent flow cytometry staining.
Isolation of cells from human lung tissue. Explanted human lung tissue was collected from patients undergoing lung transplantation who elected to participate in the Prospective Registry of Outcomes in Patients Electing Lung Transplantation (PROPEL) study at the Hospital of the University of Pennsylvania. University of Pennsylvania Institutional Review Board approval and informed written consent from patients were obtained before recruitment. We prepared single-cell suspensions of lung by chopping tissue into pieces with scissors, incubating the finely chopped tissue for 1 h with 2 mg/ml collagenase D (Roche) and 20 µg/ml DNase I (Roche) at 37 °C with shaking at 200 r.p.m., and mashing the digested tissue through a wire mesh sieve. Liquid was passed through 70-µm cell strainers, underlaid with Ficoll-Paque (GE Healthcare), and centrifuged at 1,600 r.p.m. for 20 min at room temperature with the brake off. The white lymphocyte interface layer was removed, and remaining red blood cells were lysed with ACK buffer. Cells were frozen in 90% FBS, 10% DMSO in a Nalgene Mr. Frosty container (Thermo Scientific). For flow cytometric analysis, samples were thawed and stained as a single cohort to ensure consistency.
Flow cytometry. Single-cell suspensions were stained with a combination of fluorescently conjugated monoclonal antibodies. All antibodies were from Affymetrix eBioscience and used at 1:200 dilution unless otherwise specified. For mouse studies, we used antibodies to the following mouse proteins: α 4 β 7 (DATK32), Flt3 (A2F10), KLRG1 (2F1), Ly6G (1A8), F4/80 (BM8), FcεR1 (MAR-1), CD3 (145-2C11), CD4 (GK1.5), CD5 (53-7.3), CD11b (M1/70), CD11c (N418), CD19 (eBio1D3), CD25 (PC61.5), CD45 (30-F11), CD127 (A7R34), CD90.1 (HIS51), CD90.2 (53-2.1), IL-33R (DJ8, MD Bioproducts), NK1.1 (PK136), Siglec-F (E50-2440), CD103 (2E7) and MHCII (M5/114.15.2). Streptavidin (17-4317-82) was also from Affymetrix eBioscience. For mouse studies, lineage-negative gating included markers for CD3, CD5, FcεR1, NK1.1, CD11b, B220 and CD11c. For human studies, we used antibodies to the following human proteins: CD3 (OKT3), CD4 (OKT4), CD5 (UCHT2), CD14 (61D3), CD16 (CB16), CD19 (HIB19), CD56 (B159), CD25 (BC96), CD45 (HI30), CD127 (eBioRDR5; dilution, 1:100), CRTH2 (BM16, BD Biosciences; dilution, 1:50), FcεR1α (AER-37) and IL-33R (ST2L, B4E6, MD Bioproducts; dilution, 1:100). We noted substantial variability in staining efficiency between different lots of fluorescein isothiocyanate (FITC)-conjugated anti-human IL-33R (ST2L, MD Bioproducts) and recommend that the staining efficacy of this antibody be validated for each individual lot.
For measurement of intracellular cytokine expression, cells were isolated ex vivo and stimulated in complete media (DMEM with 10% FBS (Denville Scientific), 1% l-glutamine (Gibco), 1% penicillin-streptomycin (Gibco), 25 mM HEPES buffer, and 55 µM 2-β-mercaptoethanol (Sigma-Aldrich)) with 50 ng/ml phorbol 12-myristate 13-acetate (Sigma-Aldrich), 500 ng/ml ionomycin (Sigma-Aldrich), and 10 µg/ml brefeldin A (Sigma-Aldrich) for 4 h. Cells were subsequently surface-stained with a combination of the antibodies listed above, fixed and permeabilized using a commercially available kit (BD Cytofix/Cytoperm, BD Biosciences), and stained with IL-13-Alexa Fluor 488 (eBioscience) and IL-5-phycoerythrin (eBioscience).
For measurement of intracellular arginase, cells were isolated directly ex vivo, stained with antibodies to surface antigens, fixed and permeabilized according to the manufacturer's instructions (BD Biosciences Cytofix/CytoPerm) and stained with sheep anti-human or anti-mouse Arg1 conjugated with FITC or phycoerythrin (R&D Systems).
For analysis of transcription factor expression, cells were isolated directly ex vivo, stained with antibodies to surface antigens, fixed and permeabilized according to the manufacturer's instructions (Foxp3/Transcription Factor Staining Buffer Set, eBioscience) and stained with phycoerythrin-cojugated RORγt (B2D, eBioscience) and PerCP eFluor 710-conjugated GATA3 (TWAJ, eBioscience). Ki67-phycoerythrin (BD Pharmigen), annexin V-FITC (BD Pharmigen) and 7AAD (BD Via-Probe, BD Biosciences) staining was done with commercially available kits (BD Biosciences).
For all stains except those used for annexin V and 7AAD analysis, dead cells were excluded from analysis by means of a viability stain (Live/Dead Fixable Aqua stain, Invitrogen). Samples were acquired on a custom-configuration BD LSRII or BD Fortessa flow cytometer (BD Biosciences) and analyzed using FlowJo software (v9.2, Tree Star).
Cell-trace assays. For analysis of cell division, C57BL/6J mice were treated with 100 ng of rmIL-33 (R&D Systems) i.n. every 3 d for 2-3 weeks. Lin − CD45 + CD90 + CD25 + IL-33R + ILC2s were sort-purified from lungs and labeled with 5 µM Cell Trace Violet (Invitrogen Molecular Probes). Cells were cultured for 48 h in DMEM complete media (DMEM with 10% FBS (Denville Scientific), 1% l-glutamine (Gibco), 1% penicillin-streptomycin (Gibco), 25 mM HEPES buffer, and 55 µM 2-β-mercaptoethanol (Sigma-Aldrich)) with 20 ng/ml rmIL-2, 20 ng/ml rmIL-7, 50 ng/ml rmIL-33 (all cytokines from R&D npg
